A systematic electron microscopic study on the uptake of barium sulphate nano-, submicro-, microparticles by bone marrow-derived phagocytosing cells
Source abstract
Abstract
Nanoparticles can act as transporters for synthetic molecules and biomolecules into cells, also in immunology. Antigen-presenting cells like dendritic cells are important targets for immunotherapy in nanomedicine. Therefore, we have used primary murine bone marrow-derived phagocytosing cells (bmPCs), i.e. dendritic cells and macrophages, to study their interaction with spherical barium sulphate particles of different size (40 nm, 420 nm, and 1 µm) and to follow their uptake pathway. Barium sulphate is chemically and biologically inert (no dissolution, no catalytic effects), i.e. we can separate the particle uptake effect from potential biological reactions. The colloidal stabilization of the nanoparticles was achieved by a layer of carboxymethylcellulose (CMC) which is biologically inert and gives the particles a negative zeta potential (i.e. charge). The particles were made fluorescent by conjugating 6-aminofluoresceine to CMC. Their uptake was visualized by flow cytometry, confocal laser scanning microscopy (CLSM), scanning electron microscopy (SEM), transmission electron microscopy (TEM), and correlative light and electron microscopy (CLEM). Barium sulphate particles of all sizes were readily taken up by dendritic cells and even more by macrophages, with the uptake increasing with time and particle concentration. They were mainly localized inside phagosomes, heterophagosomes, and in the case of nanoparticles also in the nearby cytosol. No particles were found in the nucleus. In nanomedicine, inorganic nanoparticles from the nanometer to the micrometer size are therefore well suited as transporters of biomolecules, including antigens, into dendritic cells and macrophages. The presented model system may also serve to describe the aseptic loosening of endoprostheses caused by abrasive wear of inert particles and the subsequent cell reaction, a question which relates to the field of nanotoxicology. STATEMENT OF SIGNIFICANCE: The interaction of particles and cells is at the heart of nanomedicine and nanotoxicology, including abrasive wear from endoprostheses. It also comprises the immunological reaction to different kinds of nanomaterials, triggered by an immune response, e.g. by antigen-presenting cells. However, it is often difficult to separate the particle effect from a chemical or biochemical reaction to particles or their cargo. We show how chemically inert barium sulphate particles with three different sizes (nano, sub-micro, and micro) interact with relevant immune cells (primary dendritic cells and macrophages). Particles of all three sizes are readily taken up into both cell types by phagocytosis, but the uptake by macrophages is significantly more prominent than that by dendritic cells. The cells take up particles until they are virtually stuffed, but without direct adverse effect. The uptake increases with time and particle concentration. Thus, we have an ideal model system to follow particles into and inside cells without the side effect of a chemical particle effect, e.g. by degradation or ion release.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Immunotherapy and Immune Responses · RNA Interference and Gene Delivery · Monoclonal and Polyclonal Antibodies Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (74)
Show source-provided references
1. Silver as antibacterial agent: Ion, nanoparticle, metal10.1002/anie.201205923 ↗
2. The transport of nanosized gene carriers unraveled by live-cell imaging10.1002/anie.200503021 ↗
3. Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model10.1053/j.gastro.2009.11.003 ↗
4. Highly efficient drug delivery with gold nanoparticle vectors for in vivo photodynamic therapy of cancer10.1021/ja801631c ↗
5. The unique role of nanoparticles in nanomedicine: imaging, drug delivery and therapy10.1039/c2cs15260f ↗
6. Inorganic nanoparticles as carriers of nucleic acids into cells10.1002/anie.200703039 ↗
7. Prophylactic and therapeutic vaccination with a nanoparticle-based peptide vaccine induces efficient protective immunity during acute and chronic retroviral infection10.1016/j.nano.2014.06.014 ↗
8. Targeting and activation of antigen-specific B-cells by calcium phosphate nanoparticles, loaded with protein antigen10.1016/j.biomaterials.2014.04.010 ↗
9. The effect of primary particle size on biodistribution of inhaled gold nano-agglomerates10.1016/j.biomaterials.2013.03.080 ↗
10. In vitro interaction of colloidal nanoparticles with mammalian cells: what have we learned thus far?10.3762/bjnano.5.161 ↗
11. Quantitative particle–cell interaction: some basic physicochemical pitfalls10.1021/acs.langmuir.6b04629 ↗
12. Nanoparticle interactions with live cells: quantitative fluorescence microscopy of nanoparticle size effects10.3762/bjnano.5.248 ↗
13. On the pathway of cellular uptake: new insight into the interaction between the cell membrane and very small nanoparticles10.3762/bjnano.7.121 ↗
14. Nanoparticle adhesion to the cell membrane and its effect on nanoparticle uptake efficiency10.1021/ja309812z ↗
15. Review of potential health risks associated with nanoscopic calcium phosphate10.1016/j.actbio.2018.07.036 ↗
16. The pathobiology and pathology of aseptic implant failure10.1302/2046-3758.55.BJR-2016-0086 ↗
17. Emperor's new clothes: Is particle disease really infected particle disease?10.1002/jor.23292 ↗
18. Nanoparticle-based B-cell targeting vaccines: tailoring of humoral immune responses by functionalization with different TLR-ligands10.1016/j.nano.2016.08.028 ↗
19. Modulation of immune response using engineered nanoparticle surfaces10.1002/smll.201502273 ↗
20. Prophylactic vaccination against hepatitis B: achievements, challenges and perspectives10.1007/s00430-014-0373-y ↗
21. Applications of nanotechnology for immunology10.1038/nri3488 ↗
22. Vaccine adjuvants: key tools for innovative vaccine design10.2174/15680266113136660183 ↗
23. Matching cellular dimensions with molecular sizes10.1038/ni.2621 ↗
24. Vaccines today, vaccines tomorrow: a perspective10.7774/cevr.2013.2.1.4 ↗
25. The potential of nanoparticles for the immunization against viral infections10.1039/C5TB00618J ↗
26. Combination of nanoparticle-based therapeutic vaccination and transient ablation of regulatory T cells strongly enhances anti-viral immunity during chronic retroviral infection10.1186/s12977-016-0258-9 ↗
27. Avidin-conjugated calcium phosphate nanoparticles as a modular targeting system for the attachment of biotinylated molecules in vitro and in vivo10.1016/j.actbio.2017.05.049 ↗
28. Understanding nanoparticle cellular entry: a physicochemical perspective10.1016/j.cis.2015.01.007 ↗
29. Endocytosis at the nanoscale10.1039/c2cs15309b ↗
30. Endocytosis of nanomedicines10.1016/j.jconrel.2010.01.036 ↗
31. Nanoparticles as transfection agents: a comprehensive study with ten different cell lines10.1039/C5RA25333K ↗
32. Targeting dendritic cells with biomaterials: developing the next generation of vaccines10.1016/j.it.2006.10.005 ↗
33. Pathogen recognition and development of particulate vaccines: does size matter?10.1016/j.ymeth.2006.05.016 ↗
34. Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy10.1016/j.vaccine.2009.03.034 ↗
35. Innovative strategies for co-delivering antigens and CpG oligonucleotides10.1016/j.addr.2008.12.013 ↗
36. Targeted antigen delivery and activation of dendritic cells in vivo: steps towards cost effective vaccines10.1016/j.smim.2011.01.001 ↗
37. Immune system targeting by biodegradable nanoparticles for cancer vaccines10.1016/j.jconrel.2013.03.010 ↗
38. Role of metallic nanoparticles in vaccinology: Implications for infectious disease vaccine development
39. Induction of type I interferons by therapeutic nanoparticle-based vaccination is indispensable to reinforce cytotoxic CD8+ T cell responses during chronic retroviral infection10.3389/fimmu.2018.00614 ↗
40. Calcium phosphate nanoparticles for transcutaneous vaccine delivery10.1166/jbn.2013.1545 ↗
41. Mesoporous silica nanoparticles act as a self-adjuvant for ovalbumin model antigen in mice10.1002/smll.201300012 ↗
42. Vaccine delivery using nanoparticles
43. Immunization of mice by hollow mesoporous silica nanoparticles as carriers of porcine circovirus type 2 ORF2 protein10.1186/1743-422X-9-108 ↗
44. Adjuvanticity and toxicity of cobalt oxide nanoparticles as an alternative vaccine adjuvant10.2217/nnm.12.35 ↗
45. Recent trends in vaccine delivery systems: a review
46. Uptake of microparticle-adsorbed protein antigen by bone-marrow-derived dendritic cells results in up-regulation of interleukin-1-alpha and interleukin-12 p40/p35 and triggers prolonged, efficient antigen presentation10.1002/eji.1830250615 ↗
47. Barium sulfate micro- and nanoparticles as bioinert reference material in particle toxicology10.1080/17435390.2016.1235740 ↗
48. Cancer immunotherapy via dendritic cells10.1038/nrc3258 ↗
49. Targeting dendritic cells – Why bother?10.1182/blood-2012-09-452078 ↗
50. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting
51. Influence of structure and properties of colloidal biomaterials on cellular uptake and cell functions10.1039/c3bm00137g ↗
52. Nanoparticle–protein interactions: therapeutic approaches and supramolecular chemistry10.1021/acs.accounts.7b00051 ↗
53. The interplay of size and surface functionality on the cellular uptake of sub-10 nm gold nanoparticles10.1021/acsnano.5b03521 ↗
54. Different endocytotic uptake mechanisms for nanoparticles in epithelial cells and macrophages10.3762/bjnano.5.174 ↗
55. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow10.1016/S0022-1759(98)00204-X ↗
56. ISDD: a computational model of particle sedimentation, diffusion and target cell dosimetry for in vitro toxicity studies10.1186/1743-8977-7-36 ↗
57. Shape and size-dependent immune response to antigen-carrying nanoparticles10.1016/j.jconrel.2015.09.069 ↗
58. Comparative activity of biodegradable nanoparticles with aluminum adjuvants: antigen uptake by dendritic cells and induction of immune response in mice10.1016/j.imlet.2011.06.002 ↗
59. Synthetic pathways to make nanoparticles fluorescent10.1039/c1nr00002k ↗
60. ISD3: a particokinetic model for predicting the combined effects of particle sedimentation, diffusion and dissolution on cellular dosimetry for in vitro systems10.1186/s12989-018-0243-7 ↗
61. Improved stimulation of human dendritic cells by receptor engagement with surface-modified microparticles10.1080/1061186031000072978 ↗
62. pH-triggered microparticles for peptide vaccination10.4049/jimmunol.173.4.2578 ↗
63. Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model10.1016/j.ijpharm.2005.03.035 ↗
64. Polymeric microspheres as stabilizing anchor for oligonucleotide delivery to dendritic cells10.1016/j.biomaterials.2005.04.022 ↗
65. Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro10.1016/j.vaccine.2004.07.050 ↗
66. Modulation of innate and adaptive immunity by biodegradable nanoparticles10.1016/j.imlet.2009.05.008 ↗
67. Poly(I:C) coated PLGA microparticles induce dendritic cell maturation10.1016/j.ijpharm.2008.08.039 ↗
68. Using carbon magnetic nanoparticles to target, track, and manipulate dendritic cells10.1016/j.jim.2010.02.009 ↗
69. The use of calcium phosphate nanoparticles encapsulating toll-like receptor ligands and the antigen hemagglutinin to induce dendritic cell maturation and T cell activation10.1016/j.biomaterials.2010.03.067 ↗
70. Efficient internalization of silica-coated iron oxide nanoparticles of different sizes by primary human macrophages and dendritic cells10.1016/j.taap.2011.03.011 ↗
71. Selective uptake of cylindrical poly(2-oxazoline) brush-antiDEC205 antibody-OVA antigen conjugates into DEC-positive dendritic cells and subsequent T-cell activation10.1002/chem.201403942 ↗
72. Toward anticancer immunotherapeutics: well-defined polymer–antibody conjugates for selective dendritic cell targeting10.1002/mabi.201400190 ↗
73. Nanoparticles target distinct dendritic cell populations according to their size10.1002/eji.200737984 ↗
74. Biological targeting with nanoparticles: state of the art10.1515/bnm-2013-0020 ↗